286 related articles for article (PubMed ID: 25074383)
1. The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions.
Orta ML; Höglund A; Calderón-Montaño JM; Domínguez I; Burgos-Morón E; Visnes T; Pastor N; Ström C; López-lázaro M; Helleday T
Nucleic Acids Res; 2014 Aug; 42(14):9108-20. PubMed ID: 25074383
[TBL] [Abstract][Full Text] [Related]
2. 5-Aza-2'-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair.
Orta ML; Calderón-Montaño JM; Domínguez I; Pastor N; Burgos-Morón E; López-Lázaro M; Cortés F; Mateos S; Helleday T
Nucleic Acids Res; 2013 Jun; 41(11):5827-36. PubMed ID: 23609537
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
Palii SS; Van Emburgh BO; Sankpal UT; Brown KD; Robertson KD
Mol Cell Biol; 2008 Jan; 28(2):752-71. PubMed ID: 17991895
[TBL] [Abstract][Full Text] [Related]
4. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
[TBL] [Abstract][Full Text] [Related]
5. XRCC1 prevents toxic PARP1 trapping during DNA base excision repair.
Demin AA; Hirota K; Tsuda M; Adamowicz M; Hailstone R; Brazina J; Gittens W; Kalasova I; Shao Z; Zha S; Sasanuma H; Hanzlikova H; Takeda S; Caldecott KW
Mol Cell; 2021 Jul; 81(14):3018-3030.e5. PubMed ID: 34102106
[TBL] [Abstract][Full Text] [Related]
6. Base excision repair defects invoke hypersensitivity to PARP inhibition.
Horton JK; Stefanick DF; Prasad R; Gassman NR; Kedar PS; Wilson SH
Mol Cancer Res; 2014 Aug; 12(8):1128-39. PubMed ID: 24770870
[TBL] [Abstract][Full Text] [Related]
7. DNA polymerase β-dependent cell survival independent of XRCC1 expression.
Horton JK; Gassman NR; Dunigan BD; Stefanick DF; Wilson SH
DNA Repair (Amst); 2015 Feb; 26():23-9. PubMed ID: 25541391
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
9. Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma
Ali R; Al-Kawaz A; Toss MS; Green AR; Miligy IM; Mesquita KA; Seedhouse C; Mirza S; Band V; Rakha EA; Madhusudan S
Cancer Res; 2018 Dec; 78(24):6818-6827. PubMed ID: 30297533
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility.
Godon C; Cordelières FP; Biard D; Giocanti N; Mégnin-Chanet F; Hall J; Favaudon V
Nucleic Acids Res; 2008 Aug; 36(13):4454-64. PubMed ID: 18603595
[TBL] [Abstract][Full Text] [Related]
11. XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.
Hirota K; Ooka M; Shimizu N; Yamada K; Tsuda M; Ibrahim MA; Yamada S; Sasanuma H; Masutani M; Takeda S
Genes Cells; 2022 May; 27(5):331-344. PubMed ID: 35194903
[TBL] [Abstract][Full Text] [Related]
12. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate.
Ström CE; Johansson F; Uhlén M; Szigyarto CA; Erixon K; Helleday T
Nucleic Acids Res; 2011 Apr; 39(8):3166-75. PubMed ID: 21183466
[TBL] [Abstract][Full Text] [Related]
13. The Cockayne syndrome protein B is involved in the repair of 5-AZA-2'-deoxycytidine-induced DNA lesions.
Burgos-Morón E; Calderón-Montaño JM; Pastor N; Höglund A; Ruiz-Castizo Á; Domínguez I; López-Lázaro M; Hajji N; Helleday T; Mateos S; Orta ML
Oncotarget; 2018 Oct; 9(80):35069-35084. PubMed ID: 30416680
[TBL] [Abstract][Full Text] [Related]
14. Base excision repair proteins are required for integrin-mediated suppression of bleomycin-induced DNA breakage in murine lung endothelial cells.
Rose JL; Reeves KC; Likhotvorik RI; Hoyt DG
J Pharmacol Exp Ther; 2007 Apr; 321(1):318-26. PubMed ID: 17202402
[TBL] [Abstract][Full Text] [Related]
15. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
Jiang Y; Yam JC; Chu WK
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
[TBL] [Abstract][Full Text] [Related]
16. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
Ali R; Alabdullah M; Alblihy A; Miligy I; Mesquita KA; Chan SY; Moseley P; Rakha EA; Madhusudan S
Cancer Lett; 2020 Jan; 469():124-133. PubMed ID: 31669203
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Anti-Cancer Treatment With a Stabilized Carbocyclic Decitabine Analogue.
Traube FR; Brás NF; Roos WP; Sommermann CC; Diehl T; Mayer RJ; Ofial AR; Müller M; Zipse H; Carell T
Chemistry; 2022 May; 28(26):e202200640. PubMed ID: 35285586
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus.
Pirotte EF; Holzhauser S; Owens D; Quine S; Al-Hussaini A; Christian AD; Giles PJ; Man ST; Evans M; Powell NG
PLoS One; 2018; 13(12):e0207934. PubMed ID: 30543656
[TBL] [Abstract][Full Text] [Related]
19. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses.
Horton JK; Stefanick DF; Gassman NR; Williams JG; Gabel SA; Cuneo MJ; Prasad R; Kedar PS; Derose EF; Hou EW; London RE; Wilson SH
DNA Repair (Amst); 2013 Sep; 12(9):774-85. PubMed ID: 23871146
[TBL] [Abstract][Full Text] [Related]
20. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
Ida N; Okura M; Tanaka S; Hosono N; Yamauchi T
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38785163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
